Literature DB >> 26650075

High level of oxysterols in neonatal cholestasis: a pitfall in analysis of biochemical markers for Niemann-Pick type C disease.

Giulia Polo, Alessandro Burlina, Francesca Furlan, Thilini Kolamunnage, Mara Cananzi, Laura Giordano, Martina Zaninotto, Mario Plebani, Alberto Burlina.   

Abstract

BACKGROUND: Niemann-Pick disease type C (NPC) is a rare lipid storage disorder characterized by progressive neurological deterioration. Diagnosing NPC is challenging as clinical signs and symptoms are variable and non-specific. Two oxysterols, cholestane-3β,5α,6β-triol (triol) and 7-ketocholesterol (7KC), have been proposed as biomarkers for aiding diagnosis of NPC. This study evaluated the use of triol and 7KC as biomarkers in cholestatic neonates with suspected NPC.
METHODS: Plasma triol and 7KC were analysed as dimethylglycine esters using an liquid chromatography - tandem mass spectrometry (LC-MS/MS) assay in selected neonates with severe cholestasis and suspected NPC (n=7), adults with cholestasis (n=15), patients with confirmed NPC (positive controls; n=11 [one child and 10 adults]), healthy subjects (negative controls; n=40 [20 children and 20 adults]), and cholestatic adults (comparative reference; n=15). The LC-MS/MS method was subjected to a number of tests for accuracy and consistency.
RESULTS: Triol and 7KC levels were substantially and significantly increased in NPC positive patients compared with healthy controls (p<0.001). However, positive results (markedly increased levels of both oxysterols) were identified in 6/7 (86%) neonates with cholestasis. Genetic testing confirmed NPC only in one neonate who had increased triol and 7KC, and increased oxysterol levels among neonates with no identified NPC gene mutations were considered likely due to biliary atresia (BA).
CONCLUSIONS: While the potential of oxysterols as NPC biomarkers has been well evaluated in older patient populations (without cholestasis), our data suggest that cholestasis might represent a pitfall in oxysterol measurements intended to aid diagnosis of NPC in affected patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26650075     DOI: 10.1515/cclm-2015-0669

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  15 in total

1.  N-acyl-O-phosphocholineserines: structures of a novel class of lipids that are biomarkers for Niemann-Pick C1 disease.

Authors:  Rohini Sidhu; Yawo Mondjinou; Mingxing Qian; Haowei Song; Arun Babu Kumar; Xinying Hong; Fong-Fu Hsu; Dennis J Dietzen; Nicole M Yanjanin; Forbes D Porter; Elizabeth Berry-Kravis; Charles H Vite; Michael H Gelb; Jean E Schaffer; Daniel S Ory; Xuntian Jiang
Journal:  J Lipid Res       Date:  2019-06-14       Impact factor: 5.922

2.  Diagnosis of niemann-pick C1 by measurement of bile acid biomarkers in archived newborn dried blood spots.

Authors:  Xuntian Jiang; Rohini Sidhu; Joseph J Orsini; Nicole Y Farhat; Forbes D Porter; Elizabeth Berry-Kravis; Jean E Schaffer; Daniel S Ory
Journal:  Mol Genet Metab       Date:  2018-08-24       Impact factor: 4.797

3.  Application of a glycinated bile acid biomarker for diagnosis and assessment of response to treatment in Niemann-pick disease type C1.

Authors:  Rohini Sidhu; Pamela Kell; Dennis J Dietzen; Nicole Y Farhat; An Ngoc Dang Do; Forbes D Porter; Elizabeth Berry-Kravis; Janine Reunert; Thorsten Marquardt; Roberto Giugliani; Charles M Lourenço; Raymond Y Wang; Nina Movsesyan; Ellen Plummer; Jean E Schaffer; Daniel S Ory; Xuntian Jiang
Journal:  Mol Genet Metab       Date:  2020-11-18       Impact factor: 4.797

4.  Advancing Diagnosis and Treatment of Niemann-Pick C disease through Biomarker Discovery.

Authors:  Xuntian Jiang; Daniel S Ory
Journal:  Explor Neuroprotective Ther       Date:  2021-12-30

5.  Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease.

Authors:  Rohini Sidhu; Pamela Kell; Dennis J Dietzen; Nicole Y Farhat; An Ngoc Dang Do; Forbes D Porter; Elizabeth Berry-Kravis; Charles H Vite; Janine Reunert; Thorsten Marquardt; Roberto Giugliani; Charles M Lourenço; Olaf Bodamer; Raymond Y Wang; Ellen Plummer; Jean E Schaffer; Daniel S Ory; Xuntian Jiang
Journal:  Mol Genet Metab       Date:  2020-01-22       Impact factor: 4.204

6.  Towards a New Diagnostic Standard for Niemann-Pick C Disease.

Authors:  Xuntian Jiang; Daniel S Ory
Journal:  EBioMedicine       Date:  2016-01-09       Impact factor: 8.143

Review 7.  Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC.

Authors:  Alberto Benussi; Maria Sofia Cotelli; Alessandro Padovani; Barbara Borroni
Journal:  F1000Res       Date:  2018-02-15

Review 8.  Unravelling new pathways of sterol metabolism: lessons learned from in-born errors and cancer.

Authors:  Yuqin Wang; William J Griffiths
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2018-03       Impact factor: 4.294

Review 9.  Recommendations for the detection and diagnosis of Niemann-Pick disease type C: An update.

Authors:  Marc C Patterson; Peter Clayton; Paul Gissen; Mathieu Anheim; Peter Bauer; Olivier Bonnot; Andrea Dardis; Carlo Dionisi-Vici; Hans-Hermann Klünemann; Philippe Latour; Charles M Lourenço; Daniel S Ory; Alasdair Parker; Miguel Pocoví; Michael Strupp; Marie T Vanier; Mark Walterfang; Thorsten Marquardt
Journal:  Neurol Clin Pract       Date:  2017-12

10.  Different Niemann-Pick C1 Genotypes Generate Protein Phenotypes that Vary in their Intracellular Processing, Trafficking and Localization.

Authors:  Hadeel Shammas; Eva-Maria Kuech; Sandra Rizk; Anibh M Das; Hassan Y Naim
Journal:  Sci Rep       Date:  2019-03-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.